Ruijin hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
NCT Number: NCT03839667
It is a multicenter, open-label, parallel-group, randomized controlled clinical trial, which is designed to enroll newly diagnosed type 2 diabetes patients with overweight or obesity. The patients are randomized to an intensive diet intervention (intermittent very-low -calorie diet), enhanced physical activity intervention (high-intensity interval training exercise prescription combined with resistance training) or standard education group (diabetes health education only, including lifestyle education and guidance) for 12 weeks. This trial will test the primary hypothesis of whether an intensive lifestyle treatment (diet or physical activity) is more effective than a standard education in glycemic control. The secondary hypotheses are to compare the intensive lifestyle treatment with a standard education on adipose distribution, metabolic parameters, metabolic molecules, Framingham Risk Scores, and quality of life, et al.
This study is active but is not currently recruiting participants.
40 year–70 year
All sexes
Interventional
Not applicable
Shanghai, Shanghai Municipality, 200025, China
The trial will recruit 324 patients from 2-3 hospitals within the China Diabetes Clinical Research Network. Eligible criteria include men and women aged 40-70 years; newly-diagnosed type 2 diabetes mellitus; BMI ≥25 kg/m2 and <40 kg/m2. Main exclusion criteria include known type 1 diabetes, usage of insulin; symptomatic cardiovascular diseases, and other serious illness. The proposed trial has 90% statistical power to detect an absolute 0.5% reduction of HbA1c changes between intensive intervention and standard education groups at a 2-sided significance level of 0.05. To achieve the proposed study objectives, we plan to perform the following specific aims:
The results will be analyzed to examine the pan-omics changes after the interventions and clarify their predictive benefits on the effects of the interventions.
After the 12-week intervention, participants will receive post-intervention follow-up visits at 24 weeks, 36 weeks, 48 weeks, and 5 years from the baseline enrollment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
Time frame: 12 weeks
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Quantify by HOMA score, which is calculated multiplying fasting plasma insulin (FPI, mIU/L) by fasting plasma glucose (FPG, mmol/L), then dividing by the constant 22.5, i.e. HOMA-IR = (FPI×FPG)/22.5.
Time frame: From enrollment to the end of follow-up at 5 years
Quantify by HOMA score, which is calculated with fasting plasma insulin (FPI, mIU/L) and fasting plasma glucose (FPG, mmol/L), i.e. HOMA-β = 20*FPI/(FPG-3.5).
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Body weight (kg) and height (m) will be combined to report BMI in kg/m^2
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
Time frame: From enrollment to the end of follow-up at 5 years
change in gut microbiota composition and proportion of specific gut flora.
Time frame: From enrollment to the end of follow-up at 5 years
Evaluated with PHQ-9 scores. The PHQ is 59-question instrument, referring to the level of interest in doing things, feeling down or depressed, difficulty with sleeping, energy levels, eating habits, self-perception, ability to concentrate, speed of functioning and thoughts of suicide. Responses range from "0" (Not at all) to "3" (nearly every day).The total sum of the responses suggests varying levels of depression. Scores range from 0 to 27. In general, a total of 10 or above is suggestive of the presence of depression.
Time frame: From enrollment to the end of follow-up at 5 years
Evaluated with HQoL scales such as Short Form 12 Health Survey Questionnaire
Time frame: From enrollment to the end of follow-up at 5 years
Evaluated with Framingham Risk Scores. Individuals with low risk have 10% or less CHD risk at 10 years, with intermediate risk 10-20%, and with high risk 20% or more.
Shanghai Jiao Tong University School of Medicine
Other
Effect of Intermittent Intensive Diet Intervention and Enhanced Physical Activity on Glycemic Control in Patients With Newly Diagnosed Type 2 diabEtes (IDEATE)
Acronym: IDEATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03050645
Diabetes Mellitus, Diabetes, Gestational
Odense, Denmark
View Trial DetailsNCT03156478
Behavior, Behavior, Animal
Kuopio, Finland
View Trial DetailsNCT05220917
Cardiovascular Events, Female Urogenital Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04323189
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Philadelphia, Pennsylvania, United States
View Trial Details